Literature DB >> 24716914

Increased expression of P2RY2, CD248 and EphB1 in gastric cancers from Chilean patients.

Gisela Aquea1, Gustavo Bresky, Domingo Lancellotti, Juan Andres Madariaga, Vittorio Zaffiri, Ulises Urzua, Sergio Haberle, Giuliano Bernal.   

Abstract

BACKGROUND: Gastric cancer (GC) ranks as one of the major causes of mortality due to cancer worldwide. In Chile, it is currently the leading cause of cancer death. Identification of novel molecular markers that may help to improve disease diagnosis at early stages is imperative.
MATERIALS AND METHODS: Using whole-genome DNA microarrays we determined differential mRNA levels in fresh human GC samples compared to adjacent healthy mucosa from the same patients. Genes significantly overexpressed in GC were validated by RT-PCR in a group of 14 GC cases.
RESULTS: The genes CD248, NSD1, RAB17, ABCG8, Ephb1 and P2RY2 were detected as the top overexpressed in GC biopsies. P2RY2, Ephb1 and CD248 showed the best sensitivity for GC detection with values of 92.9%, 85.7% and 64.3% (p<0.05), respectively. Specificity was 85.7%, 71.4% and 71.4% (p<0.05), for each respectively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24716914     DOI: 10.7314/apjcp.2014.15.5.1931

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

Review 1.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 2.  P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Authors:  Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman
Journal:  Biochem Pharmacol       Date:  2021-01-04       Impact factor: 5.858

3.  Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer.

Authors:  Mengting Ding; Hengji Zhan; Xinhui Liao; Aolin Li; Yucheng Zhong; Qunjun Gao; Yuchen Liu; Weiren Huang; Zhiming Cai
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

Review 4.  CD248: A therapeutic target in cancer and fibrotic diseases.

Authors:  Beverly A Teicher
Journal:  Oncotarget       Date:  2019-01-29

Review 5.  Purinergic Signaling in the Hallmarks of Cancer.

Authors:  Anaí Del Rocío Campos-Contreras; Mauricio Díaz-Muñoz; Francisco G Vázquez-Cuevas
Journal:  Cells       Date:  2020-07-03       Impact factor: 6.600

6.  Expression Pattern of Purinergic Signaling Components in Colorectal Cancer Cells and Differential Cellular Outcomes Induced by Extracellular ATP and Adenosine.

Authors:  Clémentine Dillard; Chloé Borde; Ammara Mohammad; Virginie Puchois; Laurent Jourdren; Annette K Larsen; Michèle Sabbah; Vincent Maréchal; Alexandre E Escargueil; Elodie Pramil
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 7.  ATP and cancer immunosurveillance.

Authors:  Oliver Kepp; Lucillia Bezu; Takahiro Yamazaki; Francesco Di Virgilio; Mark J Smyth; Guido Kroemer; Lorenzo Galluzzi
Journal:  EMBO J       Date:  2021-06-14       Impact factor: 14.012

Review 8.  Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.

Authors:  Jitka Fucikova; Irena Moserova; Linda Urbanova; Lucillia Bezu; Oliver Kepp; Isabelle Cremer; Cyril Salek; Pavel Strnad; Guido Kroemer; Lorenzo Galluzzi; Radek Spisek
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

9.  Rab17 regulates apical delivery of hepatic transcytotic vesicles.

Authors:  Anneliese C Striz; Anna P Stephan; Alfonso López-Coral; Pamela L Tuma
Journal:  Mol Biol Cell       Date:  2018-09-26       Impact factor: 4.138

10.  Identification of Key Pathways and Genes in Obesity Using Bioinformatics Analysis and Molecular Docking Studies.

Authors:  Harish Joshi; Basavaraj Vastrad; Nidhi Joshi; Chanabasayya Vastrad; Anandkumar Tengli; Iranna Kotturshetti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-24       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.